Post Traumatic Stress DisorderPhase 2SUN004NCT06902974
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD
A Phase 2 study testing Psilocybin 25 mg in people with Post Traumatic Stress Disorder and PTSD, run by Sunstone Medical at 1 site in United States.
Trial summary
A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD). Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Post Traumatic Stress Disorder, PTSD
- What is being tested?
- Psilocybin 25 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 23 May 2026to May 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Cisgender women who are at least 18 years old.
- Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current PTSD secondary to sexual assault (i.e., index trauma is sexual assault that occurred 6 or more months in the past).
- CAPS-5 score of 25 or higher at Baseline.
- Are able to swallow pills.
- Are willing to be driven home after the Dosing Session with a family member or caregiver or trusted transportation.
- Are able to complete all protocol-required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.
Show all 19Show fewer
- If able to become pregnant (i.e., with uterus and associated reproductive organs, fertile, following menarche and until becoming post-menopausal unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to the Dosing Session, and must agree to use adequate birth control through 10 days after the Dosing Session if sexually active with a biologically male partner. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).
- Must agree to inform the clinical investigators within 48 hours of any medical conditions and procedures.
- Are proficient in speaking and reading English.
- Agree to have all clinic visit sessions recorded to audio and/or video. Participants may opt out of the data analysis of the recordings.
- Agree to the following lifestyle modifications: a light breakfast 2 to 3 hours before dosing is permitted, however, participants will refrain from caffeine and nicotine 2 hours prior to dosing sessions and at least 6 hours after dosing, abstain from alcohol for 24 hours prior to dosing, not enroll in any other interventional clinical studies during the duration of the study, be driven home after the Dosing Session, and commit to medication dosing, therapy, and study procedures.
- Agree to refrain from beginning new medication and/or psychotherapy treatment.
- Continued treatment with SSRIs will be permitted if participants have been on a stable dose for 3 months or longer prior to enrollment. However, participants must be tapered off of monoamine oxidase inhibitors (MAOIs) prior to dosing.
- In addition, participants may remain in stable (> 3 months) psychotherapy.
- May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines.
- May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.
- May have alcohol or substance use disorder if participant is not in withdrawal or requiring detox. Participants must have a plan, agreed upon by the principal investigator or designated physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the principal investigator or designated physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or efficacy of the investigational treatment.
- May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the principal investigator or designated physician.
- May have hypothyroidism if taking adequate and stable thyroid replacement medication.
Who cannot join
- Male
- Condition impairing oral intake or digestive absorption.
- Are not able to give adequate informed consent.
- Significant suicide risk as defined by suicidal ideation with intend and a plan as endorsed on items 5 on the C-SSRS within the past 3 months
- Have any current problem which, in the opinion of the principal investigator or designated physician, might interfere with participation.
- Would present a serious risk to others as established through clinical interview and contact with treating therapist.
Show all 19Show fewer
- Have a history of, or a current primary, schizophrenia, schizoaffective disorder or any form of psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1, or personality disorders.
- Require ongoing concomitant therapy with a psychiatric medication with exceptions described below (see Section 6.6).
- Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment.
- Have evidence or history of recent stroke (< 6 months from signing of ICF), recent myocardial infarction (< 6 months from signing of ICF), or clinically significant arrhythmia within 1 year of signing the ICF.
- Have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration.
- Have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140/90 milligrams of Mercury [mmHg] or higher).
- Abnormal and clinically significant results on vital signs, ECG, or laboratory tests at screening and baseline
- Have symptomatic liver disease.
- Are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control if sexually active with a biologically male partner.
- Have hypersensitivity to any ingredient of the study drug.
- Positive urine drug screen for illicit drugs or drugs of abuse prior to the Dosing Session. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion.
- Current enrollment in any investigational drug or device study or participation in such within 30 days of screening.
- Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin or completion of clinical study procedures (e.g., active participation in legal proceedings).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Sunstone Medical, PC
Rockville, Maryland, 20850
Clinical Evaluation Team, 301-750-3401, clinical.specialists@sunstonetherapies.com
Celia Leeks, celia.leeks@sunstonetherapies.com
About this study
Official title: A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).
- Conditions
- Post Traumatic Stress Disorder, PTSD
- Being tested
- Psilocybin 25 mg
- Keywords
- PTSD, sexual assault, psilocybin, posttraumatic stress disorder
- Medical subject headings
- Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psilocybin 25 mgDrug
Also called Psilocybin-assisted therapy
Single dose, 25mg psilocybin, encapsulated, oral administration
| Study group | Role | What they receive |
|---|---|---|
| Psilocybin-Assisted Therapy | Experimental | This is a Phase 2, single-center, fixed dose, open-label study to explore the efficacy, safety, and tolerability of a 25 mg dose of oral psilocybin with therapy in adult women participants with PTSD secondary to an index trauma of sexual assault. There is no comparator group. Receives: Drug: Psilocybin 25 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Incidence and occurrence of treatment emergent adverse events (TEAEs) and SAEs from signing of Informed Consent Form (ICF) until the End of Study (EOS) Visit
Measured: Between ICF until End of Study (approx. 8 weeks from baseline)
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Incidence of changes in suicidal ideation/behavior (measured using the C-SSRS) score at all visits from Baseline to End of Study Visit
Measured: Between Baseline to End of Study (approx. 8 weeks from baseline)
Secondary outcomes (9)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
The CAPS is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to:
Make current (past month) diagnosis of PTSD Make lifetime diagnosis of PTSD Assess PTSD symptoms over the past week In addition to assessing the 20 DSM-5 PTSD symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization).
Scores can range from 0 (absent) - the respondent denied the problem or the respondent's report doesn't fit the DSM-5 symptom criterion" to 4 (extreme/incapacitating) "The respondent described a dramatic symptom, far above threshold.'
Measured: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Change in the PTSD Checklist (PCL-5)
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
Interpretation of the PCL-5 should be made by a clinician. The PCL-5 can be scored in different ways:
A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items.
DSM-5 symptom cluster severity scores can be obtained by summing the scores for the items within a given cluster, i.e., cluster B (items 1-5), cluster C (items 6-7), cluster D (items 8-14), and cluster E (items 15-20).
A provisional PTSD diagnosis can be made by treating each item rated as 2 = "Moderately" or higher as a symptom endorsed, then following the DSM-5 diagnostic rule which requires at least: 1 B item (questions 1-5), 1 C item (questions 6-7), 2 D items (questions 8-14), 2 E items (questions 15-20).
Measured: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Change in State-Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety (Spielberger, Gorsuch, Lushene, Vagg, \& Jacobs, 1983). It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It also is often used in research as an indicator of caregiver distress (e.g., Greene et al., 2017, Ugalde et al., 2014).
Form Y, its most popular version, has 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
Measured: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16) total score
The Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) is a 16-item self-report questionnaire used to assess the severity of depressive symptoms, with scores ranging from 0 to 27, indicating no to very severe depression.
Measured: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time to event measures: starting of antidepressant medication for any reason, starting medication for continuing PTSD or depressive symptoms, relapse from a previously recovered state (clinician judgement, supported by the PCL-5), and onset or worsening of any psychiatric symptoms. Participants who withdraw from the study will be censored from the time to event analysis.
Measured: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Change from Baseline to EOS in the Sheehan Disability Scale (SDS) total score.
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.
Measured: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Change from Baseline to EOS in the EuroQoL-5 Dimension, 5 level Scale (EQ-5D-5L) total score
The EuroQoL 5-Dimension, 5-level Scale (EQ-5D-5L) is a health-related quality of life (HRQoL) questionnaire that assesses health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 5-level scale for each dimension, ranging from no problems to extreme problems.
Measured: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Proportion of participants with clinical response in CAPS-5 total score from Baseline. Clinical response in CAPS-5 is defined in a reduction of 10 or more points.
Measured: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Proportion of participants achieving remission of PTSD symptoms as measured by the CAPS-5 following the Dosing Session. Clinical remission is defined as a Loss of Diagnosis plus a severity score < 20.
Measured: From Baseline to End of Study (approx. 8 weeks from Baseline)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2025
- Study start23 May 2026
- Primary completionNov 2027 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Traumatic Stress DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a Phase 2, single-center, fixed dose, open-label study to explore the efficacy, safety, and tolerability of a 25 mg dose of oral psilocybin with therapy in women participants with PTSD secondary to an index trauma of sexual assault.
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sunstone Medical
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manish Agrawal, MD, MSC, Principal investigator, Sunstone Medical, PC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06902974
- Sponsor's protocol ID
- 004
- Acronym
- SUN004
- Status last verified
- Jun 2026
- First submitted
- 25 Feb 2025
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data sharing not required
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
- ClinicalTrials.gov ID
- NCT06902974
- Acronym / sponsor ID
- SUN004 / 004
- Conditions
- Post Traumatic Stress Disorder, PTSD
- Keywords
- PTSD, sexual assault, psilocybin, posttraumatic stress disorder
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Sunstone MedicalUniversity, hospital or other
- Study start
- 23 May 2026 (actual)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 30 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a Phase 2, single-center, fixed dose, open-label study to explore the efficacy, safety, and tolerability of a 25 mg dose of oral psilocybin with therapy in women participants with PTSD secondary to an index trauma of sexual assault.
| Arm | Type | Receives |
|---|---|---|
| Psilocybin-Assisted Therapy | Experimental | Drug: Psilocybin 25 mgThis is a Phase 2, single-center, fixed dose, open-label study to explore the efficacy, safety, and tolerability of a 25 mg dose of oral psilocybin with therapy in adult women participants with PTSD secondary to an index trauma of sexual assault. There is no comparator group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Cisgender women who are at least 18 years old.
- Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current PTSD secondary to sexual assault (i.e., index trauma is sexual assault that occurred 6 or more months in the past).
- CAPS-5 score of 25 or higher at Baseline.
- Are able to swallow pills.
- Are willing to be driven home after the Dosing Session with a family member or caregiver or trusted transportation.
Key exclusion criteria (19 listed)
- Male
- Condition impairing oral intake or digestive absorption.
- Are not able to give adequate informed consent.
- Significant suicide risk as defined by suicidal ideation with intend and a plan as endorsed on items 5 on the C-SSRS within the past 3 months
- Have any current problem which, in the opinion of the principal investigator or designated physician, might interfere with participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psilocybin 25 mgAlso: Psilocybin-assisted therapySingle dose, 25mg psilocybin, encapsulated, oral administration | Drug | Psilocybin-Assisted Therapy |
Primary outcome
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Time frame: Between ICF until End of Study (approx. 8 weeks from baseline)
Incidence and occurrence of treatment emergent adverse events (TEAEs) and SAEs from signing of Informed Consent Form (ICF) until the End of Study (EOS) Visit
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Time frame: Between Baseline to End of Study (approx. 8 weeks from baseline)
Incidence of changes in suicidal ideation/behavior (measured using the C-SSRS) score at all visits from Baseline to End of Study Visit
9 secondary outcomes
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)
To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault
Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Individual participant dataSharing planned: Undecided. Data sharing not required
Related trials for Post Traumatic Stress Disorder
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Recruiting
Advancing Skills Through Consultation, Education, and Novel Technologies
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Manish Agrawal, MD, MSC principal investigator
Sunstone Medical, PC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Psilocybin 25 mg in people with Post Traumatic Stress Disorder and PTSD, run by Sunstone Medical at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Evaluation Team (301-750-3401, clinical.specialists@sunstonetherapies.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault (time frame: Between ICF until End of Study (approx. 8 weeks from baseline)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.